- 21 September 2017 Audentes Therapeutics announces dosing of first patient in ASPIRO for the treatment of X-Linked Myotubular Myopathy
- 20 September 2017 Spark Therapeutics Enters into Licensing Agreement with Genethon
- 25 July 2017 Restore muscle strength in Duchenne muscular dystrophy through microdystrophin
Created in 1990 by AFM-TELETHON, Genethon is fully dedicated to the design and development of gene therapy treatments for rare diseases. Its objective is to provide these innovative treatments to patients affected with rare disorders.
Genethon is developing therapies for rare neuromuscular diseases, immune system or blood disorders, eye disorders and liver diseases.